Theravance Biopharma
TBPH
TBPH
84 hedge funds and large institutions have $1.62B invested in Theravance Biopharma in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
82% less call options, than puts
Call options by funds: $394K | Put options by funds: $2.19M
Holders
84
Holding in Top 10
4
Calls
$394K
Puts
$2.19M
Top Buyers
| 1 | +$33.6M | |
| 2 | +$6.24M | |
| 3 | +$5.7M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.28M |
| 5 |
C
Chescapmanager
Baltimore,
Maryland
|
+$2.07M |
Top Sellers
| 1 | -$8.85M | |
| 2 | -$4.89M | |
| 3 | -$4.84M | |
| 4 |
D.E. Shaw & Co
New York
|
-$3.01M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$2.36M |